Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Item
http://www.wikidata.org/entity/Q35146312
Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports.Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantatiPhase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Life after transplant: are we becoming high maintenance in AML?Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party oWho Should Receive a Transplant for Acute Lymphoblastic Leukaemia?Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.Dasatinib monotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with pulmonary infection in induction remission: A case report and review of the literature
P2860

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Item
http://www.wikidata.org/entity/Q35146312
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@ast
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@en
type
label
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@ast
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@en
prefLabel
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@ast
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Tyrosine kinase inhibitors imp ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2014.116954
P433
P478
P50
P577
P5875
P698
P932